| Abstract | BACKGROUND: We previously reported that breast cancer patients who used hormone replacement therapy (HRT) had significantly lower stage tumors and higher survival than never-users. We present an update with longer follow-up, HRT use data, and in vitro research. METHODS: Our database of 292 postmenopausal breast cancer patients was updated to include HRT type, duration, and disease status. In vitro effects of estrogen (E) and/or medroxyprogesterone (MPA) on breast cancer cell growth were measured. RESULTS: Tumor prognostic factors were better and survival rates higher for both E and combination HRT users of any duration. Use greater than 10 years correlated with node-negative disease, mammographically detected tumors, and 100% survival. E supported minimal proliferation; MPA induced cell death; E+MPA results were similar to E alone. CONCLUSIONS: HRT users, regardless of type or duration of HRT use, continued to have higher survival rates. In vitro results supported the clinical finding that outcomes for users of E and E+MPA were similar. |
| Authors | Dara Christante, SuEllen Pommier, Jennifer Garreau, Patrick Muller, Brett LaFleur, Rodney Pommier
(Affiliation: Division of Surgical Oncology, Department of Surgery, Portland, OR, USA.)
|
| Journal | American journal of surgery
(Am J Surg)
Vol. 196
Issue 4
Pg. 505-11
(Oct 2008)
ISSN: 0002-9610 United States |
| PMID | 18809052
(Publication Type: Journal Article)
|
| Topics |
- Analysis of Variance
- Breast Neoplasms
(drug therapy, pathology)
- Dose-Response Relationship, Drug
- Estrogen Replacement Therapy
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Neoplasm Staging
- Postmenopause
- Prognosis
- Proportional Hazards Models
- Statistics, Nonparametric
- Survival Rate
|
